Mode
Text Size
Log in / Sign up

Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohortsDo rare gene changes linked to liver disease also raise your risk for cancer and scarring?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that rare APOB variants are associated with advanced MASLD, cirrhosis, and HCC in this meta-analysis.

This meta-analysis evaluates the association between carriage of rare APOB variants and liver disease outcomes, drawing on data from the Million Veteran Program, UK Biobank, and clinical cohorts. The study population included 510 individuals in a clinical cohort, 261 healthy controls, 43 family-based study participants, 94,885 participants in the MVP, and 417,657 in the UK Biobank. The scope encompasses advanced MASLD, hepatocellular carcinoma, cirrhosis, circulating lipids, MASLD activity, fibrosis, hepatic steatosis, and coronary artery disease.

The analysis found that APOB variants were enriched in people with advanced MASLD, with an odds ratio of 13.8 (95% CI: 2.7-70.7, P = 0.002). Variants affecting ApoB100 specifically demonstrated a 3-fold greater effect on hepatic lipid metabolism compared with those impairing both ApoB48 and ApoB100. Cross-ancestry meta-analysis yielded a pooled odds ratio of 1.82 (95% CI: 1.33-2.49) for cirrhosis and 3.53 (95% CI: 2.09-5.98) for hepatocellular carcinoma. Variants affecting specifically ApoB100 were specifically protective against coronary artery disease (P < 0.05).

Associations with lower circulating lipids (P < 0.05) and higher MASLD activity and fibrosis (P < 0.05) were also noted. The authors note that causality is suggested by the cross-ancestry meta-analysis of the study cohorts yielding pooled ORs. While practice relevance suggests APOB genotyping may enhance MASLD risk stratification, the study does not report adverse events or tolerability. Limitations include the lack of reported absolute numbers for specific outcomes and the observational nature of the cohorts.

Imagine a group of people struggling with advanced fatty liver disease, often called MASLD. Researchers found that rare changes in a gene called APOB were much more common in this group than in healthy people. In fact, having these specific gene variants was linked to a very high chance of having severe liver damage compared to those without them. This connection was clear across different groups, including large databases of veterans and people in the UK.

These same genetic changes were also tied to other serious health issues. People with these variants had higher risks of developing liver cancer and severe scarring of the liver, known as cirrhosis. Interestingly, these gene changes were also associated with lower levels of certain fats circulating in the blood, which might seem confusing but is part of the complex picture of how the liver handles fat.

The study also looked at which parts of the gene matter most. Changes affecting one specific part of the protein, ApoB100, had a much bigger impact on liver fat than changes affecting another part. This suggests that not all genetic changes are the same. However, because this was a review of existing data, we must be careful not to jump to conclusions about what this means for your personal health right now.

What this means for you:
Rare gene changes linked to fatty liver disease are also connected to higher risks of liver cancer and scarring.

Study Details

Study typeMeta analysis
Sample sizen = 510
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUNDMetabolic dysfunction-associated steatotic liver disease (MASLD) has a substantial inherited component. Rare variants in apolipoprotein B gene (APOB) have been implicated in susceptibility to liver steatosis, but their role in disease progression and outcomes is unclear.METHODSWe investigated APOB rare variants in a case-control cohort of people with advanced MASLD versus healthy controls (n = 510 and 261, respectively), a family-based study (n = 43 and literature meta-analysis), the Million Veteran Program (MVP) cohort (n = 94,885), and the UK Biobank (UKBB) (n = 417,657).RESULTSIn the clinical cohort, APOB variants were enriched in people with advanced MASLD (OR 13.8, 95% CI: 2.7-70.7, P = 0.002) and associated with lower circulating lipids, but higher MASLD activity and fibrosis (P < 0.05). In the family study, APOB variants segregated with hepatic steatosis and fibrosis (P < 0.05). Cross-ancestry meta-analysis of the study cohorts yielded pooled ORs for cirrhosis and hepatocellular carcinoma (HCC) of 1.82, 95% CI: 1.33-2.49 and 3.53, 95% CI: 2.09-5.98, respectively. Variants affecting specifically ApoB100 had a 3-fold greater effect on hepatic lipid metabolism compared with those impairing also ApoB48 and were specifically protective against coronary artery disease (P < 0.05). The variants affected cirrhosis risk similarly, but ApoB48/100 had a larger effect on HCC (P < 0.05).CONCLUSIONSRare APOB variants predispose individuals to advanced MASLD and HCC, with distinct contributions from disrupted VLDL and chylomicrons secretion. These findings highlight the interplay between hepatic and intestinal lipid handling, suggesting that APOB genotyping may enhance MASLD risk stratification and patient identification.FUNDINGEuropean Union, Italian Ministry of Health, Swedish Research Council, Veterans Health Administration, NIH.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.